Suggestions
Ken Kim, M.D.
Executive Chairman, Ark Clinical Research
Dr. Kenneth Kim is the Founder and Executive Chairman of Ark Clinical Research LLC. Here are some key details about him:
Education and Background
Dr. Kenneth Kim has an impressive educational background, having graduated summa cum laude from Harvard College and obtained his MD from Harvard Medical School.1 He also completed a fellowship at MIT Sloan School of Management and specialized in Internal Medicine and Allergy/Immunology at UCLA.1
Professional Experience
Dr. Kim is an accomplished medical professional with extensive experience in clinical research. He has been involved in over 800 clinical trials and has published more than 100 research articles in peer-reviewed journals.1 His expertise has led him to present to esteemed regulatory authorities, and he is a council member for the California Initiative to Advance Precision Medicine.1
Role at Ark Clinical Research
As the Founder and Executive Chairman of Ark Clinical Research, Dr. Kim plays a crucial role in the organization. He remains actively involved as a Principal Investigator for allergy studies in Long Beach and for metabolic studies in Fountain Valley.2
Leadership Transition
In February 2024, Dr. Kim transitioned from his role as CEO to become the Executive Chairman of Ark Clinical Research.2 This change allowed Samira Moran, who had joined as President in February 2023, to step into the role of CEO.2
Philosophy and Approach
Dr. Kim emphasizes a patient-first culture and a commitment to excellence in clinical trials at Ark Clinical Research.3 He takes pride in the organization's contribution to advancing better treatment options for the community through their research efforts.3
Dr. Kenneth Kim's LinkedIn username is kennethtkim, as mentioned in the query.
Highlights
Our monthly Asian American Health Care Professional Happy Hour occurs on the 2nd Tuesday of every month.
July 11: 6 pm. Bosscat Kitchen in Irvine
Ark Clinical Research pleased to announce positive results in the effectiveness of preventing symptomatic COVID infections in hi risk, immunocompromised patients who make up 4% of the general population but 25% of the hospitalizations, ICU admissions, and deaths. Both Long Beach and Fountain Valley sites participated and enrolled a large number of subjects. Side effects were similar to placebo.
Kudos to the Ark Team for contributing to advancing treatments!
